Clinical Trial

Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

Study acronym: ENLIGHTEN-4
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The YDAN master protocol will support two independent studies, J3R-MC-YOA1 and J3R-MC-YOA2. Each study will investigate how well and safely Eloralintide (LY3841136) works in adults with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last about 75 weeks, including screening.
Protocol Amendment History 2 changes
notable Trial sites reduced: 161 -> 152 locations 2026-08-07
notable Trial sites expanded: 154 -> 159 locations 2026-05-15
Trial Details
NCT Number NCT07353931
Lead Sponsor Eli Lilly and Company
Conditions Osteoarthritis, Overweight or Obesity
Enrollment 900 participants
Start Date 2026-02-09
Primary Completion 2028-03 (estimated)
Study Completion 2028-05 (estimated)
Updated on ClinicalTrials.gov 2026-08-06